Market Overview - U.S. stock markets are experiencing mixed premarket activity as 2025 comes to a close, following a three-day losing streak, despite significant annual gains driven by the AI and technology sectors [1][2] - Major U.S. market indexes are set to close 2025 with impressive annual gains: Nasdaq Composite is up approximately 21%, S&P 500 is up around 17%, and Dow Jones Industrial Average has climbed roughly 14% [5] Individual Stock Movements - Nike (NKE) shares rose 1.54% due to a significant stock purchase by CEO Elliott Hill [3] - Intel (INTC) gained 1.34% in premarket trading [3] - Autolus Therapeutics (AUTL) surged 5.35% after receiving a strategic upgrade from Needham & Co. [3] - Vanda Pharmaceuticals (VNDA) experienced a significant jump of 18.7% following FDA approval for its drug [3] - DigitalBridge Group (DBRG) shares surged 9.6% on news of acquisition by SoftBank Group Corp. valued at approximately $4 billion [13] - Ultragenyx Pharmaceutical (RARE) shares plunged 42.3% after disappointing Phase 3 trial results [13] - Tesla (TSLA) forecasted a decrease in fourth-quarter sales, expecting to sell 1.64 million vehicles in 2025 [13] Technology Sector Highlights - Nvidia (NVDA) remains a dominant player in AI, with ByteDance planning to increase spending on Nvidia's AI chips to ¥100 billion ($14 billion) in 2026 [13] - Meta Platforms (META) acquired AI startup Manus for over $2 billion [13] - Caterpillar (CAT) saw stock surges attributed to sales of generators related to AI infrastructure [13] Economic Data and Federal Reserve Insights - Initial Jobless Claims reported at 199,000, below the expected 220,000, indicating a slowing but stable labor market [7] - The Federal Reserve's recent meeting minutes revealed a divided debate on interest rate cuts, with expectations for further reductions in 2026 [6]

4. 英伟达拟以最高30亿美元的价格收购以色列AI初创公司AI21 Labs。 5. 亚马逊AWS将为美国政府机构AI系统投资高达500亿美元。 6. Uber、Lyft宣布与百度达成合作，计划明年在英国推Robotaxi试点。 7. 美属维尔京群岛司法部长起诉Meta，指控其故意从诈骗广告中获利。 8. "大空头"Michael Burry否认做空特斯拉，他在本月初曾称其"估值高得离谱"。 9. 特斯拉在韩国开启降价促销，Model 3最多降价940万韩元(约合4.55万元)。 10. 华纳兄弟探索据报计划再次拒绝派拉蒙修改后的收购要约。 11. 芝商所在一周内第二次上调贵金属期货保证金。 12. 迪士尼同意支付1000万美元结束有关违反儿童隐私法的指控。 13. 沃尔玛App周二一度出现服务中断，部分用户无法使用手机下单。 14. 洛克希德马丁获约5亿美元国防合约，涵盖海军作战系统、飞弹防御与海外军售相关支援。 15. 美国制药商Vanda Pharmaceuticals的晕动症药物获美国FDA批准。 16. 微博拟在未来一年内回购不超过2亿美元的股份(包括美国存托股份)。 美股时段值得关注的事件： 21 ...

Economic Data - The U.S. Chicago PMI rose to 43.5 in December, exceeding expectations of 39.8 [1] - The U.S. October S&P/CS HPI Composite - 20 n.s.a. eased to +1.3% y/y from +1.4% y/y in September, stronger than expectations of +1.1% y/y [1] Stock Market Performance - Wall Street's major indexes closed lower, with KLA Corp. and Applied Materials falling over -1% [2] - Pharmaceutical stocks like Gilead Sciences and Vertex Pharmaceuticals dropped more than -1% [2] - Citigroup slipped about -0.8% after announcing a projected $1.1 billion after-tax loss on the sale of its remaining business in Russia [2] - Molina Healthcare rose over +2% following a bullish stance from investor Michael Burry [2] Federal Reserve Insights - Minutes from the Federal Open Market Committee's December meeting indicated that most officials support additional interest-rate cuts if inflation eases [6] - Some officials expressed that it may be appropriate to keep the target range unchanged for some time after December's cut [6] - Investors anticipate at least two rate reductions next year, with an 82.8% chance of no rate change at the January FOMC meeting [7] International Market Trends - The Euro Stoxx 50 Index is down -0.22% in thin trading, with technology and mining stocks retreating [9] - The benchmark index is poised to finish 2025 up around 18%, driven by resilient economic growth and increased fiscal spending [9] - Chinese manufacturing activity returned to expansion in December, with the Manufacturing PMI at 50.1, stronger than expectations of 49.2 [12] - China's non-manufacturing PMI also rebounded to 50.2, exceeding expectations of 49.6 [12]

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose sharply in pre-market after the company announced U.S. Food and Drug Administration approval of NEREUS (tradipitant), an oral neurokinin-1 receptor antagonist, for the prevention of motion-induced vomiting in adults.Vanda Pharmaceuticals shares jumped 17.5% to $8.26 in the pre-market trading session.Here are some other stocks moving in pre-market trading.GainersAimei Health Technology Co Ltd (NASDAQ:AFJK) surged 61.6% to $133.00 in pre-market trading a ...

Market Overview - The U.S. stock market is closing 2025 on a cautious note, with major index futures edging lower, extending a three-session losing streak, and hopes for a year-end "Santa Claus" rally fading [1] - Despite the recent pullback, 2025 has been a remarkable year for equities, with the S&P 500 poised for its third consecutive year of double-digit gains [1] Premarket Trading and Futures Movements - As of early Wednesday, U.S. stock futures indicated a softer open, with Nasdaq 100 futures down 0.43%, S&P 500 futures down 0.28%, and Dow Jones futures down 0.14% [2] - The S&P 500, Nasdaq Composite, and Dow Jones all finished slightly lower on Tuesday, marking the third consecutive day of losses [2] Commodities Market - Crude oil futures were trading lower by 0.38%, around $57.72 per barrel, while Gold Spot was down 0.35% to approximately $4,324.59 per ounce [3] Major Market Indexes Performance - The S&P 500 is on track for an annual gain of 17-18%, the Dow Jones has advanced 13-14%, and the Nasdaq Composite has jumped nearly 21% in 2025 [4] - This performance marks the S&P 500's third consecutive year of double-digit returns, a rare achievement since the 1940s [4] Federal Reserve Outlook - The Federal Reserve is expected to cut rates in 2026, with uncertainty regarding the extent and pace due to internal divisions and mixed economic data [6] - The FOMC approved a quarter-point reduction in December 2025, bringing the main interest rate to a range between 3.5% and 3.75% [6] - Inflation remains above the Fed's 2% target, with unemployment rising to 4.6% in November and only 64,000 jobs added [6] Corporate Developments - Vanda Pharmaceuticals shares surged over 18% after receiving FDA approval for its drug NEREUS [13] - Nike shares rose 1.54% following CEO Elliott Hill's purchase of approximately $1 million in company shares [13] - Nvidia's stock surged approximately 180% in 2025, driven by robust demand for AI chips, with ByteDance planning to increase spending on Nvidia's AI chips to around $14 billion in 2026 [13] - Urgent.ly Inc. shares rose significantly after the adjournment of its annual stockholder meeting [13] - Applied Digital announced a proposed merger with EKSO Bionics, leading to a 40% surge in EKSO shares [13] - FONAR Corporation shares surged 28.4% after confirming its acquisition by an insider-led group [13] - Society Pass Incorporated shares jumped 16.4% following a newly priced public offering [13] - Palantir and Tesla saw their shares decline amidst concerns about technology giants' capital expenditures [13] - Boeing shares advanced 0.6% after being awarded an $8.58 billion contract by the Defense Department [13] - Meta Platforms shares ended up 1.1% following its acquisition of an AI startup for over $2 billion [13]

Market Overview - U.S. stock futures are down on New Year's Eve, with markets closing lower on Tuesday, diminishing hopes for a year-end Santa Claus rally [1] - The Dow Jones, S&P 500, Nasdaq 100, and Russell 2000 all experienced declines in premarket trading [4] - The 10-year Treasury bond yielded 4.12%, while the two-year bond was at 3.44%, with an 82.8% likelihood of the Federal Reserve maintaining current interest rates in January [3] Stocks in Focus - iSpecimen Inc. (NASDAQ:ISPC) shares rose 36.95% pre-market after announcing a $5.5 million private placement [6] - Anghami Inc. (NASDAQ:ANGH) shares increased by 56% following a report of a 97% year-over-year revenue surge [6] - Urgent.ly Inc. (NASDAQ:ULY) saw a significant rise of 52.49% on Tuesday and an additional 26.81% pre-market on Wednesday after adjourning its annual stockholder meeting [6] - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares climbed 19.06% pre-market after FDA approval of its new drug for motion-induced vomiting [13] - Core AI Holdings Inc. (NASDAQ:CHAI) shares increased by 2.78% after announcing a divestiture agreement, despite a previous drop of 5.75% [13] Economic Indicators - Investors are anticipating the Initial Jobless Claims report set to be released before market opening [2][11]

Market Overview - U.S. stock futures are down on New Year's Eve, with the Dow Jones, S&P 500, Nasdaq 100, and Russell 2000 all showing negative changes of -0.13%, -0.26%, -0.41%, and -0.42% respectively [4] - The SPDR S&P 500 ETF Trust (NYSE:SPY) is down 0.28% at $685.10, while the Invesco QQQ Trust ETF (NASDAQ:QQQ) has declined 0.41% to $616.89 [4] Economic Indicators - The 10-year Treasury bond yield is at 4.12%, and the two-year bond yield is at 3.44% [3] - The CME Group's FedWatch tool indicates an 82.8% probability that the Federal Reserve will keep interest rates unchanged in January [3] Company Performance - iSpecimen Inc. (NASDAQ:ISPC) shares are up 36.95% pre-market after announcing a $5.5 million private placement [6] - Anghami Inc. (NASDAQ:ANGH) shares have surged 56% pre-market following a report of a 97% year-over-year increase in revenue [6] - Urgent.ly Inc. (NASDAQ:ULY) shares increased by 52.49% on Tuesday and another 26.81% pre-market after adjourning its annual stockholder meeting [6] - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are up 19.06% pre-market after receiving FDA approval for its new drug NEREUS [13] - Core AI Holdings Inc. (NASDAQ:CHAI) shares rose 2.78% after announcing a definitive agreement to divest Siyata Mobile [13] Sector Performance - Consumer discretionary, materials, and financials sectors experienced the largest losses on Tuesday, while energy, real estate, and utilities sectors ended the day positively [7]

Core Viewpoint - U.S. stock futures are trading lower, with several companies making headlines due to significant stock movements following recent announcements and earnings reports [1] Group 1: Company Announcements - Oriental Rise Holdings Ltd. announced a nonbinding letter of intent to acquire a controlling stake in Hubei Daguan Tea Industry Group, leading to a 47.5% increase in its share price to $1.80 in after-hours trading [1] - Vanda Pharmaceuticals Inc. received FDA approval for NEREUS (tradipitant), resulting in a 20.2% surge in its share price to $8.45 in after-hours trading [1] - One Stop Systems Inc. agreed to sell all assets of Bressner Technology GmbH for $22.4 million, while also lowering its FY2025 sales guidance due to the discontinuation of Bressner, leading to a 1.7% increase in its share price to $7.27 in after-hours trading [1] Group 2: Earnings Reports - Ellomay Capital Ltd. reported third-quarter earnings of 93 cents per share, up from 52 cents per share in the previous year, with sales increasing to $14.944 million from $13.555 million, resulting in a 16.6% rise in its share price to $26.20 [1] - FuelCell Energy Inc. filed for a common stock offering of up to $200 million, causing a 5% decline in its share price to $7.54 in after-hours trading [1]

Core Viewpoint - Vanda Pharmaceuticals has seen a significant stock increase of over 21% following the FDA approval of its drug Nereus, which is the first treatment for exercise-induced nausea in over 40 years [1] Company Summary - Vanda Pharmaceuticals' stock price rose to $8.53 after the announcement of FDA approval for its drug Nereus [1] - The company plans to launch Nereus in the coming months [1] Industry Summary - The approval of Nereus marks a significant milestone in the pharmaceutical industry, being the first of its kind in over four decades [1]

Industry Overview - The biotech sector experienced a significant recovery in 2025, with the Nasdaq Biotechnology Index increasing by 33.8% [2] - Initial concerns regarding potential high tariffs negatively impacted the industry, but investor sentiment rebounded sharply, leading to a notable recovery [2] Drug Approvals and M&A Activity - The rally in the biotech sector was fueled by a consistent stream of new drug approvals, positive pipeline and regulatory updates, and an increase in mergers and acquisitions (M&A) activity [3] - The FDA approved over 44 drugs in 2025, indicating renewed momentum in the industry, which is expected to continue into 2026 due to investor optimism surrounding key drug approvals and innovation [4] Key Biotech Stocks - Three biotech stocks are highlighted for their potential high-impact catalysts in 2026: Denali Therapeutics (DNLI), Nuvalent, Inc. (NUVL), and Vanda Pharmaceuticals (VNDA) [5] - All three companies showed strong performance in the latter half of 2025, a trend likely to persist into 2026 due to favorable regulatory developments and promising pipeline updates [5] Denali Therapeutics - Denali has a robust pipeline targeting neurodegenerative diseases, including DNL310 (tividenofuspalfa), an enzyme replacement therapy for Hunter syndrome designed to cross the blood-brain barrier [7] - The FDA has extended the review timeline for Denali's BLA for tividenofuspalfa to April 5, 2026, following the submission of updated clinical information [11] - Denali's pipeline also includes candidates for Sanfilippo syndrome, Parkinson's disease, and ulcerative colitis [13] Nuvalent, Inc. - Nuvalent focuses on developing targeted cancer therapies, with its lead candidate zidesamtinib aimed at ROS1-positive non-small cell lung cancer (NSCLC) [14][15] - The FDA has accepted Nuvalent's NDA for zidesamtinib, with a target action date of September 18, 2026 [16] - The company also reported positive data for its second lead candidate, neladalkib, in advanced ALK-positive NSCLC [17] Vanda Pharmaceuticals - Vanda is dedicated to developing therapies for unmet medical needs, with its candidate imsidolimab targeting generalized pustular psoriasis (GPP) [18][19] - The company has requested priority review for imsidolimab, which could lead to FDA approval as early as mid-2026 [20] - Vanda has multiple regulatory catalysts ahead, including reviews for Bysanti and tradipitant, with target action dates in early 2026 [22]